Follow us on Twitter
twitter icon@FreshPatents

Dimethyl patents

      

This page is updated frequently with new Dimethyl-related patent applications.




patent app List of recent Dimethyl-related patents
 Polyester composition for extrusion blow molded containers with improved aging and drop performance patent thumbnailPolyester composition for extrusion blow molded containers with improved aging and drop performance
The present invention relates to a polyester resin for extrusion blow molded containers comprising a branched copolymer and fumed silica to improve the aged drop performance said branched copolyester is made from the reaction of purified terephthalic acid or its dimethyl ester, ethylene glycol, bifunctional diacid other than terephthalic acid, diol other than ethylene glycol, and multifunctional compound having a least 3 carboxyl groups, hydroxyl groups and/or ester forming groups thereof, said fumed silica has a particle size of 0.1 to 5 microns and is present at about 100 ppm to about 2,500 ppm based on the weight of said copolyester.. .
Auriga Polymers, Inc.


 Hydrochloride salt form for ezh2 inhibition patent thumbnailHydrochloride salt form for ezh2 inhibition
Provided herein are novel solid forms of n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.. .
Eisai R&d Management Co., Ltd.


 Novel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists patent thumbnailNovel substituted n, n-dimethylaminoalkyl ethers of isoflavanone oximes as h1-receptor antagonists
The present invention relates to compounds of formula (i), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where r1 and r2 are, independently, hydrogen, halogen, c1_3 alkyl or c1-3alkoxy; r3 is phenyl optionally substituted by r4 and r5 which are, independently hydrogen, halogen, c1-3 alkyl, c1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, n,n-dic1-3alkyl-amide, carboc1-3 alkoxy or c1-3alkylsulphone groups; r3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.. .
Polfarmex S.a.


 Method for separating n,n,n'-trimethylbisaminoethylether and/or n,n-dimethylbisaminoethylether from a mixture patent thumbnailMethod for separating n,n,n'-trimethylbisaminoethylether and/or n,n-dimethylbisaminoethylether from a mixture
(b2) separating the amide of n,n-dimethylbisaminoethylether from mixture b; and (c2) recovering n,n-dimethylbisaminoethylether from its amide by means of a transamidation reaction.. .

 Process for preparation of dimethyl fumarate patent thumbnailProcess for preparation of dimethyl fumarate
The present invention relates to a process for the preparation of dimethyl fumarate, a compound of formula i, in a purity of at least 99.0% as determined by hplc, containing less than 400 ppm of an anion of a mineral acid and less than 5 ppm of dimethyl maleate.. .
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited


 Electrospinning with reduced current or using fluid of reduced conductivity patent thumbnailElectrospinning with reduced current or using fluid of reduced conductivity
A method comprises: dissolving an aromatic side chain polymer in a terpene, terpenoid, or aromatic solvent; dissolving an inorganic salt in a polar organic solvent; mixing the salt solution and the polymer solution; and using a predominantly terpene, terpenoid, or aromatic solvent phase of the mixture as electrospinning fluid. The fluid is electrospun from spinning tip(s) onto a target substrate.
Nanostatics Corporation


 Immobilized metathesis tungsten oxo alkylidene catalysts and use thereof in olefin metathesis patent thumbnailImmobilized metathesis tungsten oxo alkylidene catalysts and use thereof in olefin metathesis
Method of making an immobilized tungsten catalyst comprising or consisting of (≡sio)xw(═o)(═cr1r2)(r3 or r4)2-x(l)z, comprising at least the following step (i): (i) reacting silica (si02) with a tungsten oxo alkylidene complex comprising or consisting of (r3)(r4)w(═o)(═cr1r2)(l)y, preferably wherein ═cr1r2 is selected from ═chc(ch3)3 or ═ch(c(ch3)2)c6h5 and r3 and r4 are independently selected from pyrrol-1-yl, 2,5-dimethylpyrrol-1-yl, or 2,5-diphenylpyrrol-1-yl, or —or, wherein r is a six membered or 10 membered aryl ring, optionally substituted.. .
Ximo Ag


 Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid patent thumbnailMethods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid
Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin d analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(s)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(s)-2-methylene-1α,25-dihydroxyvitamin d3, 2-methylene-1α,25-dihydroxy-(17e)-17(20)-dehydro-19-nor-vitamin d3, 2-methylene-19-nor-(24r)-1α,25-dihydroxyvitamin d2, 2-methylene-(20r,25s)-19,26-dinor-1α,25-dihydroxyvitamin d3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20r)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20s)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20s)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20s)-1α-hydroxyvitamin d3, 2-methylene-18,19-dinor-(20s)-1α,25-dihydroxyvitamin d3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof.
Wisconsin Alumni Research Foundation


 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury patent thumbnail4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of aki (acute kidney injury). Medicament and pharmaceutical composition thereof..
Sanofi


 Enzalutamide in combination with afuresertib for the treatment of cancer patent thumbnailEnzalutamide in combination with afuresertib for the treatment of cancer
A novel combination comprising an androgen receptor inhibitor, for example: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide or a pharmaceutically acceptable salt thereof, and an akt inhibiting compound, for example: n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which androgen receptor inhibition and/or akt inhibition is beneficial, e.g., cancer.. .
Novartis Ag


Electrolyte solution for redox flow battery and redox flow battery comprising same


The provided are an electrolyte for redox flow battery and a redox flow battery comprising the same, wherein the electrolyte for redox flow battery comprises a solute and a solvent, wherein said solute comprises at least one of anode active material and cathode active material, wherein said anode active material comprises at least one of organic compounds having a carbonyl group such as benzophenone-, benzoquinone-, dimethyl terephthalate-, and 1,4-diacetylbenzene-based organic compounds, and said cathode active material comprises at least one of amine-, tetrathiafulvalene-, and n,n,n′,n′-tetramethyl-p-phenylenediamine-based organic compounds.. .
Seoul National University R&db Foundation


Iridium complexes and organic electroluminescence device using the same


The present invention discloses an iridium complexes and the organic el device employing the iridium complexes as light emitting guest of emitting layer can display good performance like as lower driving voltage and power consumption, increasing efficiency and half-life time. Additional, the present invention provide the suitable emitting host (h1 to h6) to collocate with the energy level of iridium complexes for the present invention.
Luminescence Technology Corporation


Methods and materials to enhance high temperature rheology in invert emulsions


An invert emulsion drilling fluid, and a method of drilling with such fluid, having improved rheology at low mud weights and high temperatures. The improved rheology is effected with addition of a rheology additive of the invention comprising fatty dimer diamines or dimer diamines and an organic acid or ester of the acid.
Halliburton Energy Services, Inc.


Floor coating compositions containing supramolecular polymers


The present invention provides an aqueous floor coating composition comprising: (a) water; (b) at least one supramolecular polymer; and (c) optionally, one or more additional ingredients. The supramolecular polymer (b) comprises polymerized units derived from: (1) one or more 4h monomers which comprise a polymerizable group and a quadruple hydrogen bonding (4h) moiety; (2) at least one monomer having acid functional groups; and (3) one or more ethylenically unsaturated monomers.
Rohm And Haas Company


Process for the preparation of n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide


The invention relates to an improved process for synthesizing n,n-dicyclopropyl-4-(1,5-dimethyl-1h-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (i) compound (i) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.. .
Bristol-myers Squibb Company


Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor


An object of the present invention is to provide a compound and pharmaceutical composition showing superior stability and/or solubility, etc. And having superior flt3 inhibitory activity.
Fujifilm Corporation


Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide


The present invention relates to solid state forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1), pharmaceutical compositions thereof and methods therewith.. .
Vertex Pharmaceuticals Incorporated


Method for extraction and concentration of alkaloids using dimethyl ether


The present invention is directed to a method for the extraction and/or enrichment of alkaloids from a mixture containing such compounds. More particularly, the present invention is directed to methods for extracting one or more alkaloids using dimethyl ether..
Noramco, Inc.


Minocycline compounds and methods of use thereof


Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of mssa, mrsa, b-streptococci, viridans streptococci, enterococcus, or combinations thereof..
Paratek Pharmaceuticals, Inc.


Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity


New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.. .
Takeda Pharmaceuticals U.s.a., Inc.


An anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells


The present invention provides the compound ormeloxifene [3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy)phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like c/ebpα and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (gcsfr).
Council Of Scienticfic & Industrial Research


Methods for the synthesis of tiotropium bromide


Present invention relates to methods for preparing (1α, 2β, 4β, 5α, 7β)-7-[(hydroxidi-2-thienllacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.. .

Process for the preparation of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol


The present invention relates to a process for the preparation of (1r,2r)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.. .
GrÜnenthal Gmbh


Oxygen enrichment membrane and producing same


Provided is an oxygen enrichment membrane that has both good oxygen separation performance and good membrane physical properties (mechanical strength, ease of membrane formation, etc.), and moreover, can be used to industrially obtain a high concentration of oxygen, and a method for producing the oxygen enrichment membrane. The oxygen enrichment membrane includes, as a main component, a hydrocarbon group-containing polysiloxane network structure material which is a reaction product of a tetraalkoxysilane and a hydrocarbon group-containing dialkoxysilane.
Toyo Tire & Rubber Co., Ltd.


Pharmaceutical compositions of growth hormone secretagogue receptor ligands


The present invention relates to improvements in compositions containing peptides that are ligands of the ghs receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of h-inp-d-bal-d-trp-phe-apc-nh2, which is a ligand of the ghs receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological ph that is slowly dissolved and released into the body fluid and bloodstream.
Ipsen Pharma S.a.s.


Novel crystal form of an organic compound and process for the preparation thereof


The present invention relates to novel crystalline form ii of 17α-acetoxy-21-methoxy-11β-[4-n,n-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione, (also known as cdb-4124), processes for the preparation thereof and pharmaceutical composition comprising it. Form ii can be crystallized from different medium such as esters of c1-c4 alcohols and carboxylic acids, ketones, cyclohexane, acetonitrile, dimethylformamide, dimethyl sulfoxide, water and any mixture thereof..
Richter Gedeon Nyrt.


Losmapimod for use in treating glomerular disease


The present invention relates to a method of treating a glomerular disease with 6-(5-cyclopropylcarbamoyl-3-fluoro-2-methyl-phenyl)-n-(2,2-dimethylpropyl)-nicotinamide or a pharmaceutically acceptable salt thereof.. .
Glaxosmithkline Intellectual Property (no.2) Limited


Abuse-proofed oral dosage form


The present invention relates to an abuse-proofed oral dosage form with controlled release of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (a), at least one synthetic or natural polymer (c), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (b) and optionally a wax (d), component (c) or (d) in each case exhibiting a breaking strength of at least 500 n, preferably of at least 1000 n.. .
GrÜnenthal Gmbh


Multi-part kit system for the preparation of a disinfectant


A multi-part kit system comprising (i) a solid part a which comprises 10 to 80 wt. % of peroxy compound selected from the group consisting of khso5, k2s2o8, na2s2o8, magnesium monoperoxyphthalate hexahydrate, sodium percarbonate and sodium perborate, 0.1 to 10 wt.
The Chemours Company Fc, Llc


Method and cryopreservation of blood cells in a sterile environment


An apparatus and related method for the optimization of the cryopreservation of various types of cells, including but not limited to hematopoietic and mesenchymal stem and progenitor cells, and endothelial progenitor cells found in normal blood, placental/cord blood, bone marrow or the stromal vascular fraction of adipose tissue. The apparatus for cryopreservation of biological materials in a sterile environment comprises a cryopreservation workstation, a rigid disposable cartridge, and a freezing bag assembly.
Syngen, Inc.


Rubbery polysiloxanes carrying cyanoacrylate functions and related methods for their preparation and uses therefor


A family of silicone rubbers (e.g., polydimethylsiloxane) carrying one or more cyanoacrylate groups and their methods of production are provided. These silicone rubbers endowed with cyanoacrylate groups are useful in a variety of wound care applications, including wound closures, adhesives, sealants and skin protectors.
The University Of Akron


Method of producing pyrazino[2,1-c][1,2,4]triazine compound


A method of producing 4-(((6s,9s)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro -1h-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, including a step of adding a reaction mixture 1 containing (6s,9s)-n-benzyl-6-(4-hydroxybenzyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro -1h-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide, triethylamine and a solvent to a reaction mixture 2 containing a phosphorylating agent and a solvent.. .
Prism Pharma Co., Ltd.


Inhibitor of breast cancer resistance protein (bcrp)


Disclosed are compounds that inhibit breast cancer resistance protein (bcrp), of which compound (i-1), ((3s, 6s, 12as)-6-isobutyl-9-methoxy-3-methyl-2,3,6,7, 12, 12a- hexahydropyrazino[1′,2′: 1,6]pyrido[3,4-b]indole-1,4-dione) or a pharmaceutically acceptable salt thereof, and the compound 12, ((3s,6s,12as)-6-isobutyl-9-methoxy-3,10- dimethyl-2,3,6,7,12, 12a-hexahydropyrazino[1′,2′: 1,6]pyrido[3,4- b] indole-1,4-dione) or a pharmaceutically acceptable salt thereof. Also disclosed are methods of inhibiting bcrp or decreasing bcrp activity and methods of determining potential bcrp substrates..
Millennium Pharmaceuticals, Inc.


Method of producing silicone microspheres


A method of making silicone microspheres comprises nebulizing a silicone precursor solution comprising one or more oligomeric dimethylsiloxanes, a catalyst and a solvent into an aerosol comprising a plurality of droplets. Each droplet comprises the silicone precursor solution.
The Board Of Trustees Of The University Of Illinois


Radiation curable compositions for food packaging


An inkjet printing method includes the steps of jetting ink dots on a substrate of a plurality of radiation curable inkjet inks having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s−1, the plurality of radiation curable inkjet inks including a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of radiation curable inkjet ink; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group that the radiation curable composition further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate, a polymerizable co-initiator containing a tertiary amine and a polymeric co-initiator containing a tertiary amine; and (2) fully curing the jetted ink dots using one or more uv leds..
Agfa Graphics Nv


Improved process for the reductive amination and selective hydrogenation of substrates containing a selected halogen


Disclosed is a process for performing a chemical reaction selected from reductive amination and hydrogenation of a first functional group in an organic feed substrate, which feed substrate comprises at least one further functional group containing a halogen atom, wherein the halogen atom is selected from the list consisting of chlorine, bromine, iodine, and combinations thereof, in the presence of hydrogen and a heterogeneous catalyst comprising at least one metal from the list of pd, rh, and ru, together with at least a second metal from the list consisting of ag, ni, co, sn, cu and au. The process is preferably applied for the reductive amination of 2-chloro-benzaldehyde to form 2-chloro-benzyldimethylamine, as an intermediate in the production of agrochemically active compounds and microbiocides of the methoximinophenylglyoxylic ester series.
Taminco Bvba


Highly modified polyesters for containers


A polyester resin for use in a process in which, during an expansion step, an incompressible fluid is injected through an opening of a preform, formed of the polyester resin, to form a container. The polyester resin includes a crystallizable polyester polymer wherein the polyester polymer is comprised of acid moieties and glycol moieties, with at least 85% of the total moles of acid moieties being terephthalate derived from terephthalic acid or its dimethyl ester and at least 85% of the total moles of glycol moieties derived from ethylene glycol.
Discma Ag


Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose


The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf), more specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.. .
Forward Pharma A/s


Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose


The present invention relates to pharmaceutical compositions containing dimethyl fumarate (dmf). More specifically, the present invention relates to a pharmaceutical composition for oral use in treating psoriasis by administering a low daily dosage in the range of 375 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet..
Forward Pharma A/s


Capacitive micro-machined ultrasound transducer cell


The invention relates to a capacitive micro-machined ultrasound transducer (cmut) cell (6) comprising a cell floor (31) having a first electrode (7); a cell membrane (5) having a second electrode (7′) which opposes the first electrode and vibrates during transmission or reception of acoustic energy; a transmitter/receiver coupled to the first and second electrodes which causes the cell membrane to vibrate at an acoustic frequency and/or receives signals at an acoustic frequency; and an acoustic lens (13), overlaying the cell membrane, and having an inner surface opposing the cell membrane and an outer, patient-facing surface. According to the present invention the acoustic lens comprises at least one layer of a material selected from the group of: polybudatiene, polyether block amide (pebax), polydimethylsiloxane (pdms) and buthylrubber..
Koninklijke Philips N.v.


High molecular weight and high cationic charge glyoxalated polyacrylamide copolymers and their methods of manufacture and use


A cellulose reactive glyoxalated copolymer composition and methods of producing and using the glyoxalated copolymer composition to, for instance, strengthen paper or board are discussed. A glyoxalated copolymer composition includes an aqueous medium containing a glyoxalated copolymer, wherein the glyoxalated copolymer is obtained by reaction in an aqueous reaction medium of a dry weight ratio of glyoxalxationic copolymer.
Basf Se


Radiation curable compositions for food packaging


A radiation curable inkjet ink set includes at least a cyan radiation curable inkjet ink, a magenta radiation curable inkjet ink, a yellow radiation curable inkjet ink, and a black radiation curable inkjet ink, each having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s-1 and containing: a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of the radiation curable composition; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group that the radiation curable composition further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate, a polymerizable co-initiator containing a tertiary amine and a polymeric co-initiator containing a tertiary amine..
Agfa Graphics Nv


Radiation curable compositions for food packaging


A radiation curable inkjet ink set containing a plurality of inkjet inks having a viscosity of no more than 50 mpa·s at 25° c. And a shear rate of 90 s-1, each of the inkjet inks including a) at least one non-polymerizable, non-polymeric bisacylphosphine oxide present in a concentration of no more than 4.0 wt % based on the total weight of the inkjet ink; b) at least one monomer including at least one vinyl ether group and at least one polymerizable group selected from the group consisting of an acrylate group and a methacrylate group; and c) at least one polymerizable or polymeric thioxanthone, with the proviso that if the at least one polymerizable or polymeric thioxanthone contains no tertiary amine group, then the inkjet ink further includes at least one tertiary amine co-initiator selected from the group consisting of ethylhexyl-4-dimethylaminobenzoate and a polymerizable co-initiator containing a tertiary amine..
Agfa Graphics Nv


Methods of producing alkylfurans


Provided herein are methods of producing dialkylfurans, such as 2,5-dimethylfuran, and other alkyl furans, such as 2-methylfuran. For example, 2,5-dimethylfuran may be produced by reducing (5-methylfuran-2-yl)methanol or 2-(chloromethyl)-5-methylfuran..
Micromidas, Inc.


Glycidol preparation


This invention relates to an improved one-pot synthetic process for the preparation of glycidol from the reaction of glycerol and dimethyl carbonate. More specifically, the invention relates to a one-pot synthetic process for the preparation of glycidol comprising the reaction of glycerol and dimethyl carbonate in the presence of an ionic liquid catalyst having the formula: [cat+][x] wherein: [cat] represents one or more cationic species, and [x] represents one or more anionic species; wherein the reaction is conducted at a temperature of from 100° c.

Production 3,3-dimethyl-3,4-dihydro-1h-quinoxalin-2-one derivative and intermediate for said production method


Reducing the compound represented by formula (3) or the salt thereof to obtain the compound represented by formula (1) or the salt thereof.. .

Crystalline salts of (4s, 4as, 5ar, 12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide and methods of using the same


A crystalline mono hydrochloride salt of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4s,4as,5ar,12as)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability.
Paratek Pharmaceuticals, Inc.


3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)


Disclosed are novel pharmaceutical compositions containing 3′-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazinol-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.. .
Novartis Ag


Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative


The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-n,n-dimethyl-4-phenyl-4′,9′-dihydro-3′h-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.. .
Gruenenthal Gmbh


Synergistic antimicrobial composition


A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound.
Dow Global Technologies Llc


Method for producing emulsifiable pesticide solutions


The current invention provides a kit of parts for producing an emulsifiable pesticide solution comprising: (a) a water miscible organic solvent selected from the list of a glycol ether, a glycerol formal, dimethylsulfoxide, gamma-butyrolactone or mixtures thereof, (b) an alkoxylated alcohol with an average of 6 to 80 moles of ethylene oxide and 2 to 60 moles of propylene oxide per mole of alcohol; and (c) a pesticidal active ingredient. The invention further provides a composition for producing an emulsifiable pesticide solution, a method for producing such a composition and a method for treating an agricultural crop.
Arysta Lifescience Benelux Sprl


Composition comprising polymeric organic semiconducting compounds


The present invention relates to novel compositions comprising one or more polymeric organic semiconducting (osc) compounds and one or more organic solvents. The composition preferably comprises 3,4-dimethyl anisole as solvent.
Merck Patent Gmbh


Heat stabilizer for halogen-containing polymers


A stabilizer composition having low volatility and high efficiency comprising: (i.) 25.000% to 99.997% by weight of at least one dimethyltin compound of formula (ch3)2sn(s(ch2)mcoor1)2 wherein r1 is a linear, branched or cyclic c10-c20 alkyl group and m is 1 or 2, optionally containing unsaturations in the form of double or triple bonds; (ii.) 0.001% to 50.000% by weight of at least one mono-methyltin compound of formula ch3sn(s(ch2)ncoor2)3 wherein r2 is a linear, branched or cyclic c10-c20 alkyl group and n is 1 or 2, optionally containing unsaturations in the form of double or triple bonds; (iii.) 0.001% to 10.000% by weight of at least one tri-methyltin compound of formula (ch3)3sn(s(ch2)pcoor3) wherein r3 is a linear, branched or cyclic c10-c20 alkyl group and p is 1 or 2, optionally containing unsaturations in the form of double or triple bonds; and (iv.) 0.001% to 15.000% by weight of at least one thioester of formula hs(ch2)qcoor4 wherein r4 is a linear, branched or cyclic c10-c20 alkyl group and q is 1 or 2, optionally containing unsaturations in the form of double or triple bonds.. .
Galata Chemicals Llc


Polydimethylsiloxane sheet, optical element incorporating the same, and manufacturing method thereof


A method of manufacturing a pdms sheet that ensures good adhesion, handleability and stability to metal thin films or metal patterns of any desired shape. Given a low-molecular-weight siloxane of a cyclic structure represented by [—si(ch3)2o—]k where k is an integer of 3 to 20 inclusive, the polydimethylsiloxane sheet has a structure where the content of the low-molecular-weight siloxane at the pattern-formation surface is more than that of the low-molecular-weight siloxane at the base surface, and a spacing between the adjacent metal patterns is variable by deformation of the polydimethylsiloxane sheet..
Dai Nippon Printing Co., Ltd.


Gold(i) complexes with t-butyl phosphine and dialkyl dithiocarbamate ligands


Gold(i) complexes of formulae [au{p(t-bu)3}(s2cn(ch3)2)] (1), and [au{p(t-bu)3}(s2cn(c2h5)2)] (2) have been prepared by the reaction of equimolar amounts of [au{p(t-bu)3}(cl)] with sodium dimethyldithiocarbamate monohydrate, and sodium diethyldithiocarbamate trihydrate respectively. Both complexes (1) and (2) are iso-structural having linear geometry.
King Abdulaziz City For Science And Technology


Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and a gabapentinoid


The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-n,n-dimethyl-4-phenyl-4′,9′-dihydro-3′h-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof.. .
Gruenenthal Gmbh


Methods for detecting renal disease


The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (gfr), in an animal.

Alkenol dehydratase variants


Described are alkenol dehydratase variants having improved activity in catalyzing the conversion of a compound corresponding to the general formula cnh2no into cnh2n-2+h2o with 3<n<7. In particular, described are alkenol dehydratase variants having, e.g., an improved activity in converting but-2-en-1-ol (crotyl alcohol) into 1,3 butadiene and/or an improved activity in converting but-3-en-2-ol into 1,3 butadiene and/or an improved activity in converting 3-methylbut-2-en-1-ol (prenol) or 3-methylbut-3-en-2-ol (isoprenol) into isoprene and/or an improved activity in converting 2,3-dimethyl-but-2-en-1-ol into dimethyl-butadiene..

Enhanced oil recovery process


A process is provided for recovering oil from a hydrocarbon-bearing formation comprised of hydrocarbons and formation water. The process presented herein includes an oil recovery formulation comprising at least 75 mol % dimethyl sulfide and between 1 mol % and 18 mol % of dimethyl ether, wherein the amount of dimethyl ether in the oil recovery formulation is selected relative to the solubility of dimethyl ether in the formation water..

Polyolefin composition and process for preparing the same


A polyolefin composition comprises (a) a polypropylene polymer, (b) 1,3:2,4-bis-o-[(3,4-dimethylphenyl)methylene]-d-glucitol, and (c) 1,3:2,4-bis-o-[(3,4-dichlorophenyl)methylene]-d-glucitol. A method for producing a polyolefin composition comprises the steps of (a) providing a polypropylene polymer; (b) providing 1,3:2,4-bis-o-[(3,4-dimethylphenyl)methylene]-d-glucitol; (c) providing 1,3:2,4-bis-o-[(3,4-dichlorophenyl)methylene]-d-glucitol; (d) mixing the 1,3:2,4-bis-o-[(3,4-dimethylphenyl)methylene]-d-glucitol and the 1,3:2,4-bis-o-[(3,4-dichlorophenyl)methylene]-d-glucitol with the polypropylene polymer to produce a mixture; (e) heating the mixture to a temperature equal to or greater than the melting point of the polypropylene polymer; and (f) cooling the heated mixture to a temperature below the melting point of the polypropylene polymer, thereby producing a polyolefin composition..

Continuous reaction device for synthesizing polyoxymethylene dimethyl ethers


The present invention pertains to the technical field of energy resource chemical industry, and in particular relates to a continuous reaction device and process for synthesizing polyoxymethylene dimethyl ethers by using paraformaldehyde and methylal as feedstock or using trioxane and methylal as feedstock in the presence of an acidic catalyst. The continuous reaction device comprises multiple slurry bed stirred tank reactors connected in series or in combination of series connection and parallel connection, and also comprises an on-line solid-liquid separation device to perform separation of the reaction mixture from the catalyst.

Method of making a templating agent


A method for preparing 1-adamantyltrimethylammonium methylcarbonate or n,n-dimethyl-3,5-dimethylpiperidinium methylcarbonate is disclosed. The method comprises reacting dimethyl carbonate and 3,5-dimethylpiperidine or a 1-adamantylamine compound and in the presence of water in a sealed vessel at a temperature of from 80 to 200° c.

Process for preparing zeolite beta and use thereof


Method for preparing zeolite beta which method comprises crystallization of zeolite beta from a solution comprising a template, a silicon source and an aluminum source in which the template is polymeric compound comprising ionizable polydiallyldimethylammonium (pdadma) cationcrystallization. Furthermore, the present invention provides the use of thus prepared zeolite beta in catalysts for hydrocarbon conversions..

Lactofen and dicamba diglycol amine liquid formulations


The present invention relates to liquid agricultural formulations comprising from about 15 to about 40% w/w dicamba diglycol amine, from about 1 to about 15% w/w lactofen, from about 5 to about 40% w/w of a solvent selected from the group consisting of: (1) a solvent comprising dimethyl glutarate, dimethyl succinate, and dimethyl adipate; and (2) a solvent comprising a mixture of aromatic hydrocarbons obtained from distillation of aromatic streams derived from crude oil, from about 0.5 to about 5% w/w of a thickener with the chemical formula (mg,al)5si8o20×4h2o, and from about 2 to about 15% w/w of a polyarylphenyl ether sulphate, ammonium salt surfactant, and methods of use thereof.. .

Hydrogen-bonding surfaces for ice mitigation


Various embodiments provide ice mitigating surface coatings and methods for applying ice mitigating surface coatings. Various embodiment ice mitigating surface coatings may be formed by hydrolysis of one or more substituted n-alkyldimethylalkoxysilanes terminated with functionalities having the following characteristics with respect to water: 1) non-polar interactions; 2) hydrogen bonding through donor and acceptor interactions; or 3) hydrogen bonding through acceptor interactions only.

Anion exchange membrane for electrodialysis applications and process for the preparation thereof


The present invention relates to the preparation of novel anion exchange membranes from bicomponent or tricomponent copolymers containing both quaternizable and cross-linkable moieties. The bicomponent copolymers consisted with polyacrylonitrile and poly(2-dimethylaminoethyl) methacrylate and the tricomponent copolymers consisted with polyacryloniterle and poly2-dimethylaminoethyl) methacrylate and polyn-butyl acrylate.

Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents


Are provided. Pharmaceutical compositions comprising either the compound of formula i or formula ii are disclosed.

Conversion of oxygenates to aromatics


Described herein are processes for production of hydrocarbon products comprising contacting a feed comprising methanol and/or dimethyl ether with a catalyst composition, which comprises a zeolite having a constraint index from 1-12 and an active binder comprising a metal oxide with a dehydrogenation function, under conditions sufficient to form the hydrocarbon product, wherein the hydrocarbon product comprises aromatics, olefins, and/or paraffins. Also described herein are catalyst compositions comprising a zeolite having a 10-/12-membered ring framework and a microporous surface area of at least 150 m2/g, and from ˜1 wt % to ˜10 wt % of a zinc oxide binder, the catalyst composition having a zinc to aluminum atomic ratio from ˜0.08 to ˜8.5..

Polymorphs of arry-380, a selective her 2 inhibitor and pharmaceutical compositions containing them


Polymorphs of n4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-n6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed..

Dermal compositions


Disclosed herein are veterinary compositions including imidacloprid or an analogue thereof; a pyrethroid; a solvent selected from the group consisting of n-methyl pyrrolidone, n-ethyl pyrrolidone and mixtures thereof; and dimethyl sulfoxide. The veterinary compositions of the invention are useful in methods of controlling parasites on or within warm-blooded domesticated animals..

Electrolyte and lithium based batteries


An example electrolyte includes a solvent mixture, a lithium salt, a non-polymerizing solid electrolyte interface (sei) precursor additive, and a solvent additive. The solvent mixture includes dimethyl carbonate (dmc) and fluoroethylene carbonate (fec) present in a volume to volume ratio ranging from 20 to 1 to 1 to 20.
Gm Global Technology Operations Llc


Lubrication oil and internal-combustion engine fuel


The lubrication oil is injected with lubrication oil impregnating agent composed of dimethylalkyl tertiary amine in the range from 0.01 to 1 volume % and desirably in the range from 0.1 to 0.5 volume %. Petroleum oil fuel is injected with fuel oil impregnating agent composed of dimethylalkyl tertiary amine in the range from 0.5 to 1 volume %.

Delivery device, manufacturing system and process of manufacturing


A delivery device, manufacturing system, and process of manufacturing are disclosed. The delivery device includes a feed tube and a chemical vapor deposition coating applied over an inner surface of the feed tube, the chemical vapor deposition coating being formed from decomposition of dimethylsilane.
Silcotek Corp.


Method for producing polyoxymethylene dimethyl ethers from feedstock of concentrated formaldehyde


The present invention pertains to the technical field of energy resource chemical industry, and in particular relates to a process for producing polyoxymethylene dimethyl ethers by directly using concentrated formaldehyde aqueous solution as feedstock to catalytically react with methanol and/or methylal in a fixed bed reactor. The method of the present invention uses concentrated formaldehyde aqueous solution with a concentration of over 80% by weight to react with methanol and/or methylal, in the presence of an acidic catalyst, to produce the required polyoxymethylene dimethyl ethers.
China University Of Petroleum (eastern China)


Method for the purification of decitabine


A method of preparing purified decitabine comprises mixing crude decitabine with solvent, such as dimethylacetamide, to form a solution or suspension and forming the purified decitabine from the solution or suspension. The forming step comprises adding an anti-solvent, such as ethanol, to the solution or suspension.
Johnson Matthey Public Limited Company


Method for producing n,n-dialkylhomofarnesic acid amide


Provided are: a method for producing n,n-dialkylhomofarnesic acid amide, which is a precursor of (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2.1-b]furan that is useful as a fragrance, at a high recovery rate of a raw material, at a high purity and at a high yield; and a method for producing (±)-3a,6,6,9a-tetramethyldodecahydronaphtho[2.1-b]furan. It is a method for producing n,n-dialkylhomofarnesic acid amide, said method including reacting nerolidol with n,n-dialkylformamide dimethyl acetal under the conditions that the n,n-dialkylformamide dimethyl acetal can be refluxed, wherein the molar ratio of the n,n-dialkylformamide dimethyl acetal to the nerolidol is in a range of 1.5 to 3..
Kao Corporation


Method for manufacturing methyl fluoride


An object of the present invention is to provide a method for producing methane fluoride that is useful, for example, as a dry etching gas, the method being more suitable for industrial production. To achieve this object, the present invention provides a method including reacting (a) dimethyl sulfate and (b) at least one fluorocompound in a liquid phase, the fluorocompound (b) being at least one compound selected from the group consisting of hydrogen fluoride and hydrofluoric acid salts, or a metal fluoride, wherein when the fluoride compound (b) includes hydrogen fluoride or a hydrofluoric acid salt, the reaction is carried out without a solvent or using a polar solvent as a solvent, and when the fluoride compound (b) is a metal fluoride, the reaction is carried out using water as a solvent..
Daikin Industries, Ltd.


Antimicrobial inks and sealants


Antimicrobial inks, sealants, coatings or varnishes that are manufactured in three distinct phases: phase 1, which is an oil phase comprising ethoxylate alcohol laureth 7, didecyldimethylammonium chloride, glutaric acid dialdehyde, pinus sylvestris, alkyldimemylberizylammonium chloride, parachlorometaxylenol, ethylenediaminetetraacetic acid, 2-hydroxypropanoic acid, hydroxy-9-cis-octadecenoic acid, cetyl alcohol wax, octadecenoic acid, palmityl alcohol, and epoxy-cis-9-octadecenoic acid; phase 2, which is a micro-emulsion phase comprising ethoxylate alcohol laureth-7, cetyl alcohol wax, pinus sylvestris, and propan-2-ol and phase 3, which combines the products of phases 1 and 2 with a base to produce the ink, sealant, coating or varnish.. .

Liquid bendamustine formulation


The present invention provides stable bendamustine-containing pharmaceutical compositions suitable for long term storage. The compositions include bendamustine, a pharmaceutically acceptable salt, and/or a hydrate form thereof, a solvent mixture of n,n-dimethylacetamide and glycerin, and an antioxidant.

Coating metal foil with n-heterocyclic carbene compounds containing organic functionalities for improving metal-to-resin adhesion


A carbene-coated metal foil is produced by applying an n-heterocyclic carbene (nhc) compound to one or more surfaces of a metal foil (e.g., an electrodeposited copper foil having a surface that is smooth and non-oxidized). The nhc compound contains a matrix-reactive pendant group that includes at least one of a vinyl-, allyl-, acrylic-, methacrylic-, styrenic-, amine-, amide- and epoxy-containing moiety capable of reacting with a base polymer (e.g., a vinyl-containing resin such as a polyphenylene oxide/triallyl-isocyanurate (ppo/taic) composition).
International Business Machines Corporation


Coating metal foil with n-heterocyclic carbene compounds containing organic functionalities for improving metal-to-resin adhesion


A carbene-coated metal foil is produced by applying an n-heterocyclic carbene (nhc) compound to one or more surfaces of a metal foil (e.g., an electrodeposited copper foil having a surface that is smooth and non-oxidized). The nhc compound contains a matrix-reactive pendant group that includes at least one of a vinyl-, allyl-, acrylic-, methacrylic-, styrenic-, amine-, amide- and epoxy-containing moiety capable of reacting with a base polymer (e.g., a vinyl-containing resin such as a polyphenylene oxide/triallyl-isocyanurate (ppo/taic) composition).
International Business Machines Corporation


Coating solution for forming light-absorbing layer, and producing coating solution for forming light-absorbing layer


A method of forming a coating solution for forming a light-absorbing layer of a solar cell, including dissolving a chalcogen and at least one metal or metal compound in dimethylsulfoxide and/or water in the presence of hydrazine to obtain a homogeneous hydrazine-coordinated metal chalcogenide complex solution; and adding at least one alcohol having 1 to 5 carbon atoms to the homogeneous hydrazine-coordinated metal chalcogenide complex solution.. .
Tokyo Ohka Kogyo Co., Ltd.


Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


To provide an electrophotographic photosensitive member that can allow a high-quality image, in which photomemory after repeated use in a high-speed process is suppressed, to be output, as well as a process cartridge and an electrophotographic apparatus including the electrophotographic photosensitive member. An electrophotographic photosensitive member wherein a charge generating layer includes a gallium phthalocyanine crystal in which an organic compound is contained, wherein the organic compound is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and a charge transporting layer includes a polycarbonate resin having structural units represented by the following formula (1)..
Canon Kabushiki Kaisha


Electrophotographic photosensitive member, producing electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


The charge generating layer includes a gallium phthalocyanine crystal in which an organic compound (p) is contained, the organic compound (p) is at least one compound selected from the group consisting of dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone, the content of the organic compound (p) is 0.1% by mass or more and 1.5% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and the charge transporting layer includes a resin having a siloxane structure, and a compound (q) having a boiling point of 150° c. Or more at 1 atm..
Canon Kabushiki Kaisha


Production of dimethyl ether


The present invention concerns the production and use of feedstock streams. Specifically, the present invention provides a process for the production of a commodity using two or more feedstock streams.

Systems and methods for manufacture of dimethyl ether (dme) from natural gas and flare gas feedstock


A unique design for a mobile system that reforms flare gas or natural gas, using air without steam, to directly produce dimethyl ether (dme), a diesel substitute, is disclosed. The system first reforms the air-methane mixture at ambient atmospheric pressures, and then compresses the resulting co-hydrogen-nitrogen gas mixture to up to 600 psi, and feeds it through a combined reactor which reacts the gas mixture directly into dimethyl ether.
Pioneer Energy Inc.




Dimethyl topics:
  • Physiologic
  • Hydrochloric Acid
  • Fresnel Zone
  • Aberration
  • Ophthalmic
  • Liquid Crystal
  • Imaging System
  • Pharmaceutically Acceptable Salt
  • Pharmaceutically Acceptable Salts
  • Chloric Acid
  • Tartaric Acid
  • Fumaric Acid
  • Antagonist
  • Bradykinin
  • Enantiomer


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.1806

    4679

    3 - 0 - 103